RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2024
Top Holdings76 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 10.1M | $1.5B | 19.4% | $92.75 | +62.99% | 22 qtrssince 2018-Q4 | Increased 62 |
VAXCYTE INC | 8.2M | $560.4M | 7.1% | $36.58 | +86.76% | 16 qtrssince 2020-Q2 | Increased 64 |
Legend Biotech Corp. Sponsored ADR | 6.9M | $384.8M | 4.9% | $58.43 | -4.00% | 7 qtrssince 2022-Q3 | Increased 63 |
JANUX THERAPEUTICS INC | 9.2M | $345.1M | 4.4% | $24.54 | +53.40% | 12 qtrssince 2021-Q2 | Unchanged 0 |
| 8.3M | $244.4M | 3.1% | — | — | 12 qtrssince 2021-Q2 | Unchanged 0 | |
RHYTHM PHARMACEUTICALS INC | 5.3M | $231M | 2.9% | $23.28 | +86.10% | 22 qtrssince 2018-Q4 | Unchanged 0 |
EVOLENT HEALTH INC | 5.7M | $188.1M | 2.4% | $30.32 | +8.15% | 3 qtrssince 2023-Q3 | Increased 84 |
NewAmsterdam Pharma Company N.V. | 7.9M | $186M | 2.4% | $11.58 | +104.27% | 6 qtrssince 2022-Q4 | Unchanged 0 |
RXSIGHT INC | 3.4M | $177.6M | 2.3% | $15.69 | +228.76% | 11 qtrssince 2021-Q3 | Increased 53 |
TYRA BIOSCIENCES INC | 10.4M | $170.8M | 2.2% | $16.75 | -2.11% | 11 qtrssince 2021-Q3 | Increased 70 |
EDGEWISE THERAPEUTICS INC | 8.9M | $162.5M | 2.1% | $18.24 | 0.00% | 1 qtr | New 79 |
4D MOLECULAR THERAPEUTICS IN | 5.1M | $160.9M | 2.0% | $19.13 | +66.53% | 4 qtrssince 2023-Q2 | Increased 62 |
BIOGEN IDEC INC | 740,727 | $159.7M | 2.0% | $220.92 | -2.40% | 9 qtrssince 2022-Q1 | Increased 69 |
PEPGEN INC | 10.7M | $157.1M | 2.0% | $11.43 | +28.62% | 8 qtrssince 2022-Q2 | Increased 61 |
GERON CORP | 46.2M | $152.5M | 1.9% | $2.12 | +55.48% | 16 qtrssince 2020-Q2 | Unchanged 0 |
89BIO INC | 12.8M | $148.6M | 1.9% | — | — | 18 qtrssince 2019-Q4 | Increased 53 |
DYNE THERAPEUTICS INC | 5M | $140.7M | 1.8% | $28.39 | 0.00% | 1 qtr | New 69 |
APOGEE THERAPEUTICS INC | 2M | $131.4M | 1.7% | $21.30 | +211.97% | 3 qtrssince 2023-Q3 | Unchanged 0 |
DAY ONE BIOPHARMACEUTICALS I | 7.8M | $129M | 1.6% | $18.91 | -12.64% | 12 qtrssince 2021-Q2 | Unchanged 0 |
NKARTA INC | 10.8M | $116.8M | 1.5% | $21.20 | -49.00% | 15 qtrssince 2020-Q3 | Increased 62 |
RA CAPITAL MANAGEMENT, L.P. manages $7.9B across 76 positions as of Q1 2024. Top holdings: ASND (19.4%), PCVX (7.1%), LEGN (4.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 21 new positions, 7 exits, 18 increased. Top move: EVH (INCREASED, conviction 84). Portfolio: $7.9B across 76 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer